Venous thrombosis and the 'Wessler test'

Thrombosis and Haemostasis

Volumn 76, Issue 1, 1996, Pages 1-4

  Thomas, Duncan P ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; HEPARIN;

ANIMAL MODEL; BLOOD; EXPERIMENTAL ANIMAL; HYPERCOAGULABILITY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; THROMBOGENICITY; VEIN THROMBOSIS; VENOUS STASIS;

EID: 0030035334     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650511     Document Type: Short Survey

References (52)

1. Wessler S. Studies in intravascular coagulation. 1. Coagulation changes in isolated venous segments. Journal of Clinical Investigation 1952; 31: 1011-4.
2. Wessler S. Studies in intravascular coagulation. II. A comparison of the effect of dicumarol and heparin on clot formation is isolated venous segments. Journal of Clinical Investigation 1953; 32: 650-4.
3. Wessler S. Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis. Journal of Clinical Investigation 1955; 34: 647-51.
4. Wessler S, Reiner L, Freiman DG, Reimer SM, Lertzman M. Serum induced thrombosis. Studies of its induction and evolution under controlled conditions in vivo. Circulation 1959; 20: 864-74.
5. Wessler S, Reimer SM, Sheps MC. Biological assay of a thrombosis-inducing activity in human serum. Journal of Applied Physiology 1959; 14: 943-6.
6. Wessler S, Morris LE. Studies in intravascular coagulation. IV. The effect of heparin and dicumarol on serum-induced venous thrombosis. Circulation 1955; 12: 553-6.
7. Wessler S. Thrombosis in the presence of vascular stasis. American Journal of Medicine 1962; 33: 648-66.
8. Hewson W. An experimental inquiry into the properties of the blood. London: Cadell 1771: p. 20.
9. Lister, J. The Croonian Lecture on the Coagulation of the Blood. Lancet 1863; 2: 149.
10. Hayem G. L'Hematoblaste. 1923, Les Presses Universitaires de France, Paris: p. 120.
11. Feissly R. La stabilité du fibrinogène in vivo. Compt rendu Soc Biol 1925; 92: 319.
12. Gitel SN, Stephenson RC, Wessler S. In vitro and in vivo correlation of clotting protease activity: effect of heparin. Proceedings of the National Academy of Sciences, USA 1977; 74: 3028-32.
13. Ratnoff OD, Crum JD. Activation of Hageman factor by solutions of ellagic acid. Journal of Laboratory and Clinical Medicine 1963; 62: 1006-7.
14. Reimer SM, Thomas DP. The role of factors XII, XI and IX in serum and plasma-induced thrombosis. American Journal of Physiology 1963; 205: 1265-9.
15. Thomas DP, Wessler S. Stasis thrombosis induced by bacterial endotoxin. Circulation 1963; 27: 339-45.
16. Deykin D. The role of the liver in serum-induced hypercoagulability. Journal of Clinical Investigation 1963; 45: 256-60.
17. Thomas DP, Merton RE, Lewis WE, Barrowcliffe TW. Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb Haemost 1981; 45: 214-8.
18. Carter CJ, Kelton JG, Hirsh J, Cerskus AL, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins and heparin. Blood 1982; 59: 1239-45.
19. Boneu B, Buchanan MR, Cade JF, Van Ryn J, Fernandez FA, Ofosu FA, Hirsh J. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thrombosis Research, 1985; 40: 81-9.
20. Van Ryn-McKenna J, Gray E, Weber E, Ofosu FA, Buchanan MR. Effects of sulphated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost 1989; 61: 7-9.
21. Brill-Edwards P, van Ryn-McKenna J, Cai L, Ofosu FA, Buchanan MR. Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy. Thromb Haemost 1992; 68: 424-7.
22. Virchow R. Cellular Pathology. 1860; London, John Churchill.
23. McLachlin J, Paterson JC. Some basic observations on venous thrombosis and pulmonary embolism. Surgery, Gynecology and Obstetrics 1951; 93: 1.
24. Sevitt S. Pathology and pathogenesis of deep vein thrombi. In: Venous Problems. Bergan JJ, Yao JST (eds). Year Book Chicago; 1968, pp. 257-79.
25. Hume M, Sevitt S, Thomas DP. Venous thrombosis and pulmonary embolism. Cambridge, Harvard University Press 1970.
26. Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. Journal of Clinical Pathology 1974; 27: 517-28.
27. Busch PC, Owen WG. Interaction of thrombin with endothelium. In: Pathobiology of the endothehal cell. Nossel HL, Vogel HJ (eds). 1982; New York; Academic Press: p. 97.
28. Dahlbäck B, Stenflo J. A natural anticoagulant pathway: proteins C, S, C4b-binding protein and thrombomodulin. In: Thromb Haemost. Bloom AL, Forbes, CD, Thomas, DP & Tuddenham, EGD. eds. 3rd. Ed Churchill Livingstone. Edinburgh: 1994; 671-98.
29. Broze GJ. The tissue factor pathway of coagulation: factor VII, tissue factor and tissue factor pathway inhibitor. In: Thrombosis and Haemostasis, Bloom, AL, Forbes, CD, Thomas, DP & Tuddenham, EDG. 3rd. Eds. Edinburgh, Churchill Livingstone: 1994: pp. 349-77.
30. Rapaport SI, Rao VM. The Tissue Factor pathway: how it became a »prima ballerina«. Thromb Haemost 1995; 74: 7-17.
31. Merton RE, Hockley, Gray E, Poole S, Thomas DP. The effect of interleukin-1 on venous endothelium - an ultrastructural study. Thromb Haemost 1991; 66: 725-9.
32. The DVTENOX study group. Markers of hemostatic system activation in acute deep venous thrombosis - evolution during the first days of heparin treatment. Thromb Haemost 1993; 70: 909-14.
33. Bounameaux H, de Moerloose P, Ferner A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous Ihromboembolism: an overview. Thromb Haemost 1994; 71: 1-6.
34. Mannucci PM, Bauer KA, Gringeri A, Bazegar S, Santagostino E, Tradati FC, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 606-11.
35. Thomas DP. Venous thrombogenesis. British Medical Bulletin, 1994; 50: 803-12.
36. Wessler S, Freiman DG, Ballon SD, Katz JH, Wolff R, Wolf E. Experimental pulmonary embolism with serum-induced thrombi. American Journal of Pathology 1961; 38: 89-101.
37. Freiman DG, Wessler S, Lertzman M. Experimental pulmonary embolism with serum-induced thrombi aged in vivo. American Journal of Pathology 1961; 39: 95-102.
38. Thomas DP, Stein M, Tanabe G, Rege V, Wessler S. Mechanism of bronchoconstriction produced by thromboemboli in dogs. American Journal of Physiology 1964; 206: 1207-12.
39. Levy SE, Stein M, Totten RS, Bruderman I, Wessler S, Robin ED. Ventilation-perfusion abnormalities in experimental pulmonary embolism. Journal of Clinical Investigation 1965; 44: 1699-1707.
40. Stein M, Thomas DP. The role of platelets in the acute pulmonary response toendotoxin. Journal of Applied Physiology 1967; 23: 47-52.
41. Thomas DP, Gurewich V, Stuart RK. Epinephrine potentiation of platelet aggregation: its effect on mortality from experimental pulmonary embolism. Journal of Laboratory and Clinical Medicine 1968; 71: 955-63.
42. Gurewich V, Cohen M, Thomas DP. Humoral factors in massive pulmonary embolism: an experimental study. American Heart Journal 1968; 76: 784-94.
43. Wessler S, Gitel SN, Bank H, Martinowitz U, Stephenson RC. An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits. Thromb Haemost 1978; 40: 486-98.
44. Gitel SN, Wessler S. The antithrombotic effects of warfarin and heparin following infusion of tissue thromboplastin in rabbits: clinical implications. Journal of Laboratory and Clinical Medicine 1979; 94: 481-8.
45. Gitel SN, Wessler S. Dose-dependent antithrombotic effect of warfarin in rabbits. Blood 1983; 61: 435-8.
46. Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with high affinity for antithrombin III. Thromb Haemost 1982; 47: 244-8.
47. Merton RE, Thomas DP, Havercroft SJ, Barrowcliffe TW, Lindahl U. High and low affinity heparin compared with unfractionated heparin as antithrombotic drugs. Thromb Haemost 1984; 51: 254-6.
48. Barrowcliffe TW, Johnson EA, Thomas DP. Low molecular weight heparin. Chichester & New York: John Wiley, 1991.
49. Thomas DP, Merton RE, Barrowcliffe TW. Anticoagulant activity of heparin and heparin fragments. Annals of the New York Academy of Sciences 1989; 556: 132-45.
50. Lusher JM. Thrombogenicity associated with factor IX concentrates. Seminars in Hematology 1991; 28: 3-5.
51. McLaughlin LF, Drummond O, MacGregor IR. Thrombogenicity of factor IX concentrates. Hemophilia 1995; 1, (suppl. 3): 16-8.
52. Ferranti TJ, Misra BR, Schaub RG, Keith JC. Recombinant human factor IX has low thrombogenicity in the Wessler stasis model. Thromb Haemost 1995; 73: 1014.